Loading
A small single-centre trial in Los Angeles is testing whether adding a worm medicine to an immunotherapy antibody is safe, and then whether it shrinks triple-negative breast cancer that has spread. It opened in 2023 and has not reported.
The study opened on 13 October 2023, plans 34 patients and expects to reach its primary completion in October 2026 (ClinicalTrials.gov NCT05318469). Phase 1 finds the recommended phase 2 dose of ivermectin by counting adverse events, and phase 2 measures the objective response rate, with progression-free survival, overall survival and duration of response as secondary endpoints (ClinicalTrials.gov NCT05318469). No results have been posted and no publication is indexed on Europe PMC (ClinicalTrials.gov NCT05318469). The registry entry for the later ICONIC trial reports that among the first nine treated patients no treatment-related serious adverse events were observed (ClinicalTrials.gov NCT07487805).
Shares Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer (with 2026 expression of concern), Systematic drug repurposing, Ivermectin, No incentive to repurpose cheap drugs.
Shares Systematic drug repurposing, Ivermectin, No incentive to repurpose cheap drugs.
Shares Agenus, Balstilimab, Immune checkpoint inhibitors.
Shares Agenus, Balstilimab, Immune checkpoint inhibitors.
Shares Agenus, Balstilimab, Immune checkpoint inhibitors.
Shares Agenus, Balstilimab, Immune checkpoint inhibitors.
Shares Agenus, Balstilimab, Immune checkpoint inhibitors.
Shares Agenus, Balstilimab.